A case report on Duchene muscular dystrophy in an Indian family

Saurabh Kishor; Vivek Kumar Verma

doi:10.18203/2320-6012.ijrms20221497

Authors

Saurabh Kishor Department of General Medicine, ASMC Hardoi, Uttar Pradesh, India
Vivek Kumar Verma Department of General Medicine, ASMC Hardoi, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20221497

Keywords:

Calf hypertrophy, Corticosteroid, Muscle weakness, Gower sign

Abstract

Duchenne muscular dystrophy (DMD) is commonest X-linked syndrome muscular dystrophy in the children, present in early childhood and characterized by the proximal muscle weakness and the calf hypertrophy in exaggerated boys. There is generally delay in the motor development and ultimately wheelchair confinement leading to premature death from cardiac or the respiratory complications. For treatment we use various modalities like corticosteroid therapy. We also used intermittent positive pressure ventilation that could help in developments in function, quality of life, ambulation and life expectancy though novel therapies still focus to provide the cure for this disease. Clinically, it is categorized by the progressive muscle wasting ultimately leading to the premature death. Here we presented a case of Duchene muscular dystrophy in a 13 year old boy with clinical presentation.

Metrics

Metrics Loading ...

Author Biographies

Saurabh Kishor, Department of General Medicine, ASMC Hardoi, Uttar Pradesh, India

Senior Resident, Dept. of General Medicine, ASMC Hardoi Uttar Pradesh India

Vivek Kumar Verma, Department of General Medicine, ASMC Hardoi, Uttar Pradesh, India

Associate Professor & Head, Dept. of General Medicine, ASMC Hardoi Uttar Pradesh

References

Eashwar VMA, Yuwasri D, Gopalakrishnan S. Duchenne Muscular Dystrophy: Case Report. 2020;7(7):6058-62.

Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004;5(9):872-6.

Bertoni C, Rando TA. Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA–DNA chimeric oligonucleotides. Hum Gene Ther. 2002;13:707-18.

Suneja B, Suneja ES, Adlakha VK, Chandna P. A rare case report of neurodegeneration disease: Duchenne muscular dystrophy in two male siblings. Int J Clin Pediatr Dent. 2015;8:163-5.

Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93.

Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Physical Rehabil Med. 2013;56(6):443-54.

Opas M, Michalak M. Duchenne muscular dystrophy. Encyclopedia of Life Sciences. London: Nature Publishing Group. 2001.

Singh V, Sinha S, Mishra S, Chaturvedi LS, Pradhan S, Mittal RD et al. Proportion and pattern of dystrophin gene deletions in north Indian Duchenne and Becker muscular dystrophy patients. Hum Genet. 1997;99:206-8.

Mallikarjuna Rao GN, Hussain T, Geetha-Devi N, Jain S, Chandak GR, Ananda Raj MP. Dystrophin gene deletions in South Indian Duchenne muscular dystrophy patients. Indian J Med Sci. 2003;57:1-6.

Jansen M, de Groot IJ, van Alfen N, Geurts AC. Physical training in boys with Duchenne muscular dystrophy: The protocol of the no use is disuse study. BMC Pediatr. 2010;10:55.